FT : Gold and silver under scrutiny as index changes spark wave of bullion sales

Gold and silver under scrutiny as index changes spark wave of bullion sales
Cocoa set for large-scale buying during index rebalance period

A wave of bullion selling worth more than $10bn is providing the first “big test” of the market in 2026, as last year’s stratospheric run-up in gold and silver prices comes under pressure.

Funds that track commodity indices are rebalancing their holdings and are expected to sell about $6.1bn of silver and $5.6bn of gold during the annual rebalancing window running this year from January 8 to 15, according to calculations from JPMorgan.

“It is the industry’s first big test of how sustainable the December moves are, given we are starting 2026 at such a high base,” said Nicky Shiels, analyst at MKS Pamp.

Benchmark commodity indices such as the Bloomberg Commodity index have to rebalance their weightings once a year to maintain target allocation levels. Funds that track the indices have to buy or sell holdings as a result.

In some years, the market impact is muted but, due to recent big moves in some commodity prices, this year’s rebalancing is expected to have a bigger effect.

This may put pressure on bullion prices but could also provide an opportunity for keen investors to buy the dip — which happened last year, analysts point out. During the 2025 rebalancing window, enforced selling was met with even greater buying, sending prices up.

Gold prices have fallen 0.6 per cent since Tuesday’s close, while silver prices are down more than 4 per cent in the same period.

The yellow metal soared more than 60 per cent in 2025, with silver rising more than 160 per cent.

Gregory Shearer, an analyst at JPMorgan, said silver would see the biggest sales of any commodity during the rebalancing. He estimates net selling of silver equivalent to about 10 per cent of the value of all the open derivatives contracts on trading venue Comex.

Traders are also watching cocoa, which has been re-included in the BCOM. Funds will have to buy a quantity of cocoa equivalent to about 30 per cent of open interest on the Ice exchange in London, according to Kona Haque, head of research at commodity trader ED&F Man.

“This is huge,” she said, adding that the changes helped explain cocoa’s sharp rally in November, when the index announced its inclusion.

Haque said some speculative funds may already have moved ahead of the rebalancing but added that “even then, there should be a decent bullish impact on cocoa prices just on the pure index funds buying”.

“Cocoa people have talked of little else for three months,” said Jonathan Parkman of Marex, adding that there were concerns the rebalancing could prompt short covering of a large speculative position in London.  

Cocoa prices fell nearly 50 per cent in 2025, after a record-breaking rally in 2023 and 2024 driven by supply shortages in West Africa, which grows more than two-thirds of the world’s beans.

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • AXTI -13.3%, BBNX -12.5%, WDFC -8.7%, OLN -7.4%, PCRX -4.1%, ASTL -0.9%
Other news:
  • AQST -43.6% (announces regulatory development for Anaphylm sublingual film and provides business update)
  • FLYX -13.6% (stock offering)
  • AVTX -6.5% (files for $750 mln mixed securities shelf offering)
  • RIO -3.5% (Glencore confirms preliminary discussions with Rio Tinto on potential combination)
  • GOLF -2.3% (entered into a subscription and shareholders' agreement)
  • GM -1.9% (expects $6 bln charge in Q4 related to reducing EV production and impairments)
  • PSTL -1.9% (provides Q4 update on activity)
  • CATX -1.1% (presents updated interim data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • TLRY +10.7%, IMOS +9.8% (Dec revs), INSM +5.7% (guidance), LQDA +5.4% (reports preliminary 2025 YUTREPIA sales and positive cash flow), SNWV +1.3% (guidance), GBX +1.2%, CRI +1%, TSM +0.8% (Dec revs), ASX +0.5% (Dec revs)
Other news:
  • OKLO +17.1% (announce agreement in support of 1.2 gw nuclear energy development in Southern Ohio)
  • QURE +14.8% (announces a Type A meeting with the U.S. Food and Drug Administration has been scheduled to discuss the Biologics License Application data package to support accelerated approval of AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease)
  • VST +14% (Vistra Corp. and Meta (META) announce agreements to support nuclear plants in PJM and add new nuclear generation to the grid)
  • KALV +13.2% (provides update on EKTERLY launch)
  • SSII +5.9% (names new Global COO and CFO)
  • RKT +5.8% (Trump comments about mortgage bonds)
  • MESO +4.9% (reports Ryoncil quarterly sales jump 60% to $35.1 mln)
  • INTC +2.6% (President Trump said he had a great meeting with CEO in Truth Social post)
  • CSIQ +2.6% (prices offering of $200 mln of convertible senior notes due 2031)
  • FMS +2.2% (accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned)
  • NWPX +2% (first commercial use of its Permalok Radial Bending Joint)
  • JBI +2% (aquires Kiwi II Construction)
  • LGND +2% (Agenus and Ligand (LGND) amended purchase and sale agreement)
  • SVRA +1.9% (exclusive distribution agreement for MOLBREEVI)
  • SERA +1.7% (provides investor updates in presentation)
  • DLX +1.3% (collaboration with Visa)
  • LMT +1.3% (State Department has made a determination approving a possible Foreign Military Sale to the Government of Denmark of AGM-114R Hellfire Missiles and related equipment for an estimated cost of $45 million)
  • APPN +1% (Appian (APPN) announced that it would press its trade secret claims against Pegasystems)

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Altria Group (MO) upgraded to Buy from Neutral at UBS, tgt $63
    • Allogene Therapeutics (ALLO) upgraded to Outperform from Market Perform at Citizens, tgt $5
    • American Airlines (AAL) upgraded to Positive from Neutral at Susquehanna, tgt $20
    • Antofagasta (ANFGY) upgraded to Buy from Neutral at Goldman
    • Ardelyx (ARDX) upgraded to Overweight from Neutral at Piper Sandler
    • Array Technologies (ARRY) upgraded to Buy from Hold at TD Cowen, tgt $12
    • Cardinal Health (CAH) upgraded to Buy from Neutral at Citigroup
    • CareTrust REIT (CTRE) upgraded to Outperform from Market Perform at BMO Capital, tgt $43
    • Choice Hotels (CHH) upgraded to Buy from Hold at Truist, tgt $126
    • Cleveland-Cliffs (CLF) upgraded to Overweight from Equal Weight at Morgan Stanley, tgt $17
    • Cousins Properties (CUZ) upgraded to Outperform from Market Perform at BMO Capital, tgt $31
    • CrowdStrike (CRWD) upgraded to Buy from Hold at Berenberg, tgt $600
    • DiamondRock Hospitality (DRH) upgraded to Buy from Hold at Truist, tgt $11
    • Donaldson (DCI) upgraded to Buy from Hold at Jefferies, tgt $120
    • Edwards Lifesciences (EW) upgraded to Buy from Hold at TD Cowen, tgt $97
    • Expeditors (EXPD) upgraded to Buy from Neutral at BofA Securities
    • FedEx (FDX) upgraded to Buy from Neutral at BofA Securities, tgt $365
    • Generac (GNRC) upgraded to Outperform from Neutral at Robert W. Baird
    • H2O America (HTO) upgraded to Buy from Neutral at BTIG Research, tgt $61
    • Host Hotels (HST) upgraded to Buy from Hold at Truist, tgt $21
    • Independence Realty Trust (IRT) upgraded to Outperform from Market Perform at BMO Capital, tgt $22
    • Lockheed Martin (LMT) upgraded to Buy from Hold at Truist, tgt $605
    • L'Oreal (LRLCY) upgraded to Buy from Neutral at UBS
    • Marks & Spencer (MAKSY) upgraded to Buy from Hold at Berenberg
    • Marriott International (MAR) upgraded to Outperform from Market Perform at BMO Capital, tgt $370
    • MoonLake Immunotherapeutics (MLTX) upgraded to Buy from Neutral at BTIG Research, tgt $24
    • NuScale Power (SMR) upgraded to Neutral from Underperform at BofA Securities, tgt $28
    • Ormat Technologies (ORA) upgraded to Buy from Hold at TD Cowen, tgt $130
    • Oscar Health (OSCR) upgraded to Neutral from Sell at UBS, tgt $17
    • Quanta Services (PWR) upgraded to Buy from Neutral at Seaport Research
    • RPM International (RPM) upgraded to Overweight from Neutral at JPMorgan, tgt $115
    • Schneider National (SNDR) upgraded to Buy from Neutral at BofA Securities, tgt $32
    • SiteOne Landscape Supply (SITE) upgraded to Outperform from Sector Perform at RBC Capital, tgt $151
    • SolarEdge Technologies (SEDG) upgraded to Buy from Hold at TD Cowen, tgt $38
    • Sotera Health (SHC) upgraded to Overweight from Neutral at Piper Sandler, tgt $24
    • Southwest Airlines (LUV) upgraded to Overweight from Underweight at JPMorgan, tgt $60
    • Sun Country Airlines (SNCY) upgraded to Positive from Neutral at Susquehanna, tgt $20
    • UPS (UPS) upgraded to Neutral from Underperform at BofA Securities, tgt $114
    • Waste Management (WM) upgraded to Buy from Neutral at UBS, tgt $260
  • Downgrades:
    • Adobe (ADBE) downgraded to Market Perform from Outperform at BMO Capital, tgt $375
    • Alcon (ALC) downgraded to Hold from Buy at Stifel
    • American Homes 4 Rent (AMH) downgraded to Market Perform from Outperform at BMO Capital, tgt $37
    • American Tower (AMT) downgraded to Market Perform from Outperform at BMO Capital, tgt $185
    • AXT Inc. (AXTI) downgraded to Neutral from Buy at B. Riley, tgt $18
    • Ballard Power Systems (BLDP) downgraded to Hold from Buy at TD Cowen
    • Beta Bionics (BBNX) downgraded to Neutral from Buy at BofA Securities
    • BMW (BMWYY) downgraded to Underweight from Equal Weight at Barclays
    • Confluent (CFLT) downgraded to Market Perform from Outperform at Citizens
    • Emerson (EMR) downgraded to Hold from Buy at TD Cowen, tgt $150
    • Equity Residential (EQR) downgraded to Market Perform from Outperform at BMO Capital, tgt $68
    • Essex Property Trust (ESS) downgraded to Market Perform from Outperform at BMO Capital, tgt $280
    • GE Vernova (GEV) downgraded to Neutral from Outperform at Robert W. Baird
    • HealthEquity (HQY) downgraded to Sell from Neutral at Goldman, tgt $89
    • Hudson Pacific Properties (HPP) downgraded to Market Perform from Outperform at BMO Capital, tgt $11
    • iHeartMedia (IHRT) downgraded to Sell from Neutral at Goldman, tgt $3.50
    • Intuitive Machines (LUNR) downgraded to Hold from Buy at Stifel, tgt $20
    • Mattel (MAT) downgraded to Neutral from Buy at Goldman, tgt $21
    • Northrop Grumman (NOC) downgraded to Hold from Buy at Truist, tgt $623
    • Nucor (NUE) downgraded to Equal Weight from Overweight at Morgan Stanley, tgt $180
    • Omega Healthcare Investors (OHI) downgraded to Market Perform from Outperform at BMO Capital, tgt $45
    • On Holding (ONON) downgraded to Hold from Buy at Williams Trading, tgt $47
    • Plug Power (PLUG) downgraded to Hold from Buy at TD Cowen, tgt $2
    • Qualcomm (QCOM) downgraded to Neutral from Outperform at Mizuho, tgt $175
    • Regency Centers (REG) downgraded to Neutral from Outperform at Mizuho, tgt $74
    • Scorpio Tankers (STNG) downgraded to Underperform from Buy at BofA Securities
    • Societe Generale (SCGLY) downgraded to Reduce from Buy at Kepler Cheuvreux
    • Steel Dynamics (STLD) downgraded to Equal Weight from Overweight at Morgan Stanley, tgt $194
    • Zimmer Biomet (ZBH) downgraded to Sell from Neutral at Goldman, tgt $93
    • Zillow Group (ZG) downgraded to Neutral from Outperform at Mizuho, tgt $70
  • Others:
    • Alexandria Real Estate (ARE) initiated with an Equal Weight at Morgan Stanley, tgt not specified
    • Autodesk (ADSK) initiated with a Buy at Rothschild Redburn, tgt $375
    • Bowman Consulting Group (BWMN) initiated with a Neutral at JPMorgan, tgt $40
    • BridgeBio Oncology (BBOT) initiated with an Outperform at Raymond James, tgt $24
    • Casey's General Stores (CASY) initiated with a Buy at BofA Securities
    • CAVA Group (CAVA) initiated with an Outperform at Telsey Advisory, tgt $85
    • Claritev (CTEV) initiated with an Equal Weight at Wells Fargo, tgt $33
    • Consolidated Edison (ED) initiated with a Hold at TD Cowen, tgt $105
    • Constellation Energy (CEG) initiated with a Buy at TD Cowen, tgt $440
    • Crescent Energy (CRGY) initiated with a Market Perform at BMO Capital, tgt $10
    • Dominion Energy (D) initiated with a Hold at TD Cowen, tgt $65
    • Doximity (DOCS) initiated with an Outperform at RBC Capital, tgt $59
    • DraftKings (DKNG) initiated with a Hold at Texas Capital, tgt $39
    • Entergy (ETR) initiated with a Buy at TD Cowen, tgt $108
    • Fennec Pharmaceuticals (FENC) initiated with an Overweight at Piper Sandler
    • Flutter Entertainment (FLUT) initiated with a Buy at Texas Capital, tgt $294
    • Healthpeak Properties (DOC) initiated with a Neutral at Goldman, tgt $17
    • Hinge Health (HNGE) initiated with an Overweight at Wells Fargo, tgt $68
    • LB Pharmaceuticals (LBRX) initiated with a Buy at Roth Capital
    • Magnolia Oil & Gas (MGY) initiated with an Outperform at BMO Capital, tgt $27
    • Monopar Therapeutics (MNPR) initiated with an Overweight at Morgan Stanley, tgt $115
    • Murphy USA (MUSA) initiated with an Underperform at BofA Securities
    • National Energy Services Reunited (NESR) initiated with a Buy at BofA Securities
    • Omega Healthcare Investors (OHI) initiated with a Buy at Goldman, tgt $54
    • Omada Health (OMDA) initiated with an Equal Weight at Wells Fargo, tgt $17
    • Palisade Bio (PALI) initiated with a Buy at B. Riley, tgt $7
    • Phreesia (PHR) initiated with an Overweight at Wells Fargo, tgt $30
    • RadNet (RDNT) initiated with an Overweight at KeyBanc, tgt $92
    • Rapt Therapeutics (RAPT) initiated with an Overweight at Piper Sandler, tgt $95
    • Scholar Rock (SRRK) initiated with a Buy at Citigroup, tgt $55
    • Sonida Senior Living (SNDA) initiated with a Neutral at Robert W. Baird
    • TIC Solutions (TIC) initiated with an Overweight at JPMorgan, tgt $16
    • Ventas (VTR) initiated with a Buy at Goldman, tgt $94
    • Vor Biopharma (VOR) initiated with a Buy at Citigroup, tgt $50
    • Waystar Holding (WAY) initiated with an Overweight at Wells Fargo, tgt $41
    • Wynn Resorts (WYNN) initiated with a Buy at Texas Capital, tgt $155

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • KALV +18.1%, OKLO +17.8%, TLRY +9.6%, VST +9.2%, RKT +6.8%, SSII +5.9%, MESO +5.7%, CSIQ +4.1%, IMOS +3.9%, INTC +2.5%, TTAM +2%, JBI +2%, SVRA +1.9%, ASX +1.8%, QTRX +1.4%, SNWV +1.3%, FRO +1.2%, PRAX +1.2%, LMT +1.2%, GWRE +0.9%, KRYS +0.8%, EBS +0.7%, TSM +0.7%
  • Gapping down:
    • FLYX -15.1%, BBNX -13.8%, AXTI -13.5%, WDFC -8.7%, OLN -7.1%, AVTX -6.5%, PCRX -4.1%, RIO -3.5%, GM -1.9%, PSTL -1.9%, AEHR -1.1%, ASTL -0.9%, GBX -0.8%, GLUE -0.7%, ZG -0.6%, NG -0.6%

>>> Europe : Brokers Upgrades & Downgrades - 9th of January 2026 V3(++)

>>> Up
* Airbnb Raised to Equal-Weight at Wells Fargo; PT $128
* Airbnb Raised to Equal-Weight at Barclays; PT $120
* Altri Raised to Outperform at Grupo Santander; PT 5.49 euros
* Altria Raised to Buy at UBS; PT $63
* American Eagle PT Raised to $25 from $20 at JPMorgan (++)
* Antofagasta Raised to Buy at Goldman; PT 4,000 pence
* Auto Trader Raised to Equal-Weight at Morgan Stanley
* BAE PT Raised to 2,600 pence from 2,500 pence at UBS (++)
* Balfour Beatty PT Raised to 800 pence at Berenberg (+)
* BNP Paribas Raised to Overweight at JPMorgan; PT 102 euros
* Choice Hotels Raised to Buy at Truist Secs; PT $126 (++)
* Cleveland-Cliffs Raised to Overweight at Morgan Stanley; PT $17
* Costain PT Raised to 190 pence from 175 pence at Berenberg (+)
* CrowdStrike Raised to Buy at Berenberg; PT $600
* Host Hotels Raised to Buy at Truist Secs; PT $21 (++)
* L'Oreal Raised to Buy at UBS; PT 430 euros
* Man Group Raised to Buy at BofA (++)
* Marriott Intl Raised to Outperform at BMO; PT $370 (+)
* Marks & Spencer Raised to Buy at Berenberg; PT 415 pence
* Norske Skog Raised to Buy at Pareto Securities; PT 25 kroner
* Rolls-Royce PT Raised to 1,625 pence from 1,350 pence at UBS (++)
* Saab PT Raised to 710 kronor from 660 kronor at UBS (++)
* Scout24 Raised to Overweight at Morgan Stanley; PT 114 euros
* SMG SW Raised to Overweight at Morgan Stanley
* Thales PT Raised to 380 euros from 360 euros at UBS (++)
* UPS Raised to Neutral at BofA; PT $114 (++)
* Victoria's Secret PT Raised to $75 from $60 at JPMorgan (++)

>>> Down
* AB Foods Cut to Hold at Shore Capital (+)
* Alcon AG Cut to Hold at Stifel; PT 63.96 Swiss francs
* Aviva Cut to Equal-Weight at Morgan Stanley; PT 670 pence
* BE Semiconductor Cut to Hold at Kepler Cheuvreux
* BMW Cut to Underweight at Barclays; PT 82.50 euros
* Cellnex Cut to Neutral at Goldman; PT 31 euros
* DWS Cut to Neutral at BofA (++)
* Euronext Cut to Neutral at BofA (++)
* GE Vernova Cut to Neutral at Baird; PT $649
* Hannover Re Cut to Equal-Weight at Morgan Stanley; PT 270 euros
* Herantis Pharma Cut to Reduce at Inderes; PT 2.50 euros
* M&G Cut to Equal-Weight at Morgan Stanley; PT 285 pence
* Mattel Cut to Neutral at Goldman; PT $21 (+)
* Metso Cut to Neutral at BofA
* Neste Cut to Neutral at BofA; PT 22 euros (++)
* Nucor Cut to Equal-Weight at Morgan Stanley; PT $180
* Porsche Cut to Underweight at Barclays; PT 40 euros
* Repsol Cut to Underperform at BofA; PT 15 euros (++)
* Rightmove Cut to Underweight at Morgan Stanley; PT 510 pence
* Sandvik Cut to Neutral at BofA
* Sartorius Stedim Cut to Sector Perform at RBC; PT 240 euros
* Sartorius Cut to Sector Perform at RBC; PT 260 euros
* Siltronic Cut to Hold From Buy, Target Cut to EUR53.50 From EUR57.50 by MWB Research (++)
* SocGen Cut to Reduce at Kepler Cheuvreux
* Steel Dynamics Cut to Equal-Weight at Morgan Stanley; PT $194
* Unicaja Cut to Neutral at BofA (+)
* Vale ADRs Cut to Neutral at Safra; PT $16
* WAG Payment Cut to Equal-Weight at Morgan Stanley; PT 124 pence

>>> Initiation
* Air France-KLM Rated New Neutral at CIC; PT 12 euros (+)
* Autodesk Rated New Buy at Rothschild & Co Redburn; PT $375
* Avanza Rated New Neutral at Goldman; PT 371 kronor (+)
* Dassault Systemes Rated New Neutral at Rothschild & Co Redburn
* DraftKings Rated New Hold at Texas Capital; PT $39
* Empire Metals Ltd Rated New Speculative Buy at Canaccord (+)
* FinecoBank Reinstated Buy at Goldman; PT 25.30 euros (+)
* Flutter Rated New Buy at Texas Capital; PT $294
* Newron Pharma Rated New Buy at Roth Capital Partners
* Nordnet Rated New Buy at Goldman; PT 310 kronor (+)
* Novo ADRs Rated New Outperform at CICC; PT $73.50
* Pharma Mar Rated New Outperform at Grupo Santander; PT 102 euros
* Sabadell Reinstated Neutral at BofA; PT 3.60 euros (++)
* Swissquote Rated New Neutral at Goldman; PT 479 Swiss francs (+)

>>> Call
* European Insurers Lag; Hannover and Aviva Cut by Morgan Stanley (++)
* Morgan Stanley Sees ‘Notably Improved’ Sentiment on China Stocks
* SocGen Double-Downgraded at Kepler on Possible Ayvens Deal (++)

FT : UK hedge fund trader Chris Rokos pays himself £477mn

UK hedge fund trader Chris Rokos pays himself £477mn
Rokos Capital returned 31% in 2024 following wild swings in equity, bond and commodity markets

Chris Rokos paid himself almost half a billion pounds last year as his macro hedge fund soared in a highly volatile period for markets.

Rokos Capital Management paid £477mn in profits to its highest-paid partner in the year to March 2025, the largest amount since a £509mn payout in 2021, accounts filed to UK Companies House showed.

While the accounts do not disclose the identity of the highest-paid partner, this is widely believed to be Rokos, who is the firm’s founder, majority owner and key risk taker.

Rokos Capital declined to comment.

The hedge fund makes bets on key economic indicators such as inflation and interest rates through asset classes including commodities, equities and bonds.

Chris Rokos is one of the world’s best-known hedge fund traders and a co-founder of macro hedge fund behemoth Brevan Howard.

Rokos Capital was up 21 per cent last year in its lowest-fee share class, according to a person who had seen the numbers, enjoying wild swings in equity, bond and commodity markets that proved the best year for macro hedge funds since 2009.

The fund returned 31 per cent in 2024, which primarily contributed to the profits in this set of accounts, and 8.8 per cent the previous year.

The accounts also showed that revenues more than doubled from £445mn to £1.2bn and that the profit pool available for partners was a record £940mn.

Rokos is the main risk taker at his $22bn hedge fund, supported by analysts and a team of senior investment professionals the firm calls investment officers. This approach is in contrast to most other hedge funds of a similar size, which have multiple key portfolio managers that make trades independently of each other.

After a disastrous 2021 when the fund lost a quarter of its value, performance has radically improved, increasing 51 per cent in 2022, with positive returns every subsequent year.

Other hedge funds, including Caxton and Graham, also enjoyed a strong 2025, as the sector enjoyed winning bets on copper, gold and on a weakening dollar.

Rokos’s old firm Brevan Howard had a mixed year, with its Master fund up an estimated 0.75 per cent and its Alpha Strategies fund up roughly 8 per cent.

>>> JPM Healthcare Conference San Francisco

JPM European Pharma & Biotech names will present over four days at the J.P. Morgan Healthcare Conference (Jan 12–15, 2026, all times PST), with M&A firepower and BD optionality a core cross‑stock theme. Below is a concise calendar plus key M&A‑relevant angles in a Bloomberg‑style note.

Conference calendar (PST)
Monday, Jan 12
  • 07:30 – GSK
  • 08:15 – Argenx
  • 09:00 – Novartis
  • 09:45 – Sanofi
  • 11:15 – Merck KGaA
  • 13:30 – Galderma
  • 14:15 – Oxford Nanopore
  • 15:00 – Roche
Tuesday, Jan 13
  • 07:30 – GSK (listed under Tuesday in schedule table, but also shown in header as Tuesday presenter; handbook table aligns with GSK at 07:30)
  • 09:00 – AstraZeneca
  • 09:45 – Novo Nordisk / Sandoz
  • 10:30 – Lonza
  • 11:15 – Bayer
  • 13:30 – Zealand
  • 15:45 – Genmab
  • 16:30 – Ipsen
Wednesday, Jan 14
  • 07:30 – UCB
  • 11:15 – Recordati
  • 13:30 – Zealand (as per main schedule table)
  • 15:00 – Bachem
Thursday, Jan 15
  • 10:30 – Molecular Partners
(Grifols has no conference presentation; Oxbio and various small caps are covered in the handbook but not in the core EU pharma schedule table.)

Cross‑sector M&A setup
  • Large‑cap firepower remains substantial: JPM estimates EU large caps have sizeable deal capacity at 3.0x 2025E Net Debt/EBITDA, led by Roche, Novartis, Novo, Sanofi, Bayer and Merck, reinforcing scope for structured BD and bolt‑ons rather than mega‑mergers.
  • Post‑2030 patent cliff drives external growth: Report explicitly flags “firepower” as increasingly important as EU large caps look beyond 2030, keeping M&A and in‑licensing at the centre of equity stories into and beyond JPM week.

Name‑by‑name M&A / BD angles
Novartis (Mon 09:00)
  • Balance sheet and firepower charts place Novartis among the group with significant headroom at ~3x 2025E Net Debt/EBITDA, underpinning continued BD optionality.
  • Pipeline grid highlights multiple late‑stage assets (pelacarsen, zigakibart, del‑desiran, abelacimab, del‑zota, del‑brax), tilting strategy toward targeted bolt‑on deals and licensing to complement in‑house programs rather than transformational M&A.
Sanofi (Mon 09:45)
  • Sector section emphasises the need to supplement organic amlitelimab and immunology build‑out with externally sourced assets as Sanofi manages high‑single‑digit EPS ambitions and FX headwinds.
  • AATD and immunology readouts plus continued focus on specialty care keep Sanofi positioned as both a buyer (immunology, rare disease) and occasional partner of choice.
Merck KGaA (Mon 11:15)
  • JPM explicitly flags potential “corporate” moves including a partnership announcement for precemtabart tocentecan (M9140) and “potential M&A / business development in Life Sciences.”​
  • Disposal of Surface Solutions and acquisition of SpringWorks reshape the portfolio; 2026 guidance discussion links FX and BD to EBITDA trajectory, signalling ongoing portfolio reshuffling rather than scale M&A.
Roche (Mon 15:00)
  • High absolute firepower and relatively moderate leverage (Net Debt/EBITDA) place Roche at the top end of EU large‑cap deal capacity.JPM_European_Pharma-Conference-Book-1.pdf​
  • Obesity, neurology and hematology assets (petrelintide, CT‑996, CT‑388, Evrysdi combinations) are highlighted as pipeline pillars, with external innovation likely to remain a lever to sustain growth vs. consensus.JPM_European_Pharma-Conference-Book-1.pdf​
GSK (Tue 07:30)
  • Guidance narrative focuses on managing U.S. vaccine pricing headwinds and investing into oncology and respiratory; M&A frame is more selective, with emphasis on targeted assets rather than large scale deals.JPM_European_Pharma-Conference-Book-1.pdf​
  • Newsflow list includes a potential Capital Markets Day for the new CEO strategy in 3Q26, where M&A / BD framework will likely be a key topic.
AstraZeneca (Tue 09:00)
  • Strong 2025‑30 growth profile but still reliant on external innovation in oncology and rare disease; multiple pivotal datasets (Dato‑DXd, AZD0901, camizestrant, eplontersen) reduce urgency for large M&A but support bolt‑on appetite using balance‑sheet headroom.
  • Cardiometabolic and obesity adjacency (Eplontersen, etc.) positions AZN as a logical future consolidator in cardiometabolic and genetic disease platforms.​
Novo Nordisk (Tue 09:45)
  • Obesity and diabetes cash flows underpin significant theoretical deal capacity, but handbook stresses focus on internal obesity pipeline (CagriSema, Amycretin, ziltivkemab) and competitive dynamics vs. Lilly rather than large M&A.
  • BD read‑through is more about tuck‑ins or technology deals that extend GLP‑1/GIP/tri‑agonist leadership.
Bayer (Tue 11:15)
  • One of the larger firepower contributors, but litigation overhang (glyphosate, dicamba) constrains near‑term big‑ticket M&A.
  • JPM frames Bayer as a positive catalyst watch into asundexian OCEANIC‑Stroke data and multiple litigation milestones, implying any sizeable M&A is more a medium‑term option once legal visibility improves.
Lonza (Tue 10:30)
  • Mid‑cap CDMO strongly positioned as a target of pharma outsourcing wallets; JPM highlights CDMO‑driven growth with margin expansion and specific 2026 newsflow around Vacaville contracting and CHI divestment.
  • Strategic narrative is about portfolio optimisation (divest CHI, add capacity/tech via smaller deals) rather than selling the group or pursuing large acquisitions.
Galderma (Tue 13:30)
  • Aesthetics and dermatology growth plus Ipsen arbitration around a terminated early‑stage R&D collaboration underscore BD intensity in the space.
  • Guidance assumptions include continued investment in commercial and R&D, suggesting scope for further bolt‑on brand/asset deals while keeping leverage in check.
Genmab (Tue 15:45)
  • Heavy reliance on partnered programs (Darzalex, Kesimpta, Epkinly) positions Genmab structurally as a BD platform story, but JPM’s cuts to 2026 EPS vs. consensus underscore the execution risk.
  • 2026‑27 data (Epkinly 1L DLBCL, petosemtamab) could be triggers for broader strategic interest from large caps seeking antibody / bispecific know‑how.
Ipsen (Tue 16:30)
  • Ipsen explicitly flagged with potential 2026 “M&A to add to the pipeline,” alongside a potential update on the Galderma arbitration.
  • With expected 2026 core margin at ~30% and growth skewed to specialty, Ipsen screens both as an acquirer of late‑stage specialty assets and as a mid‑cap consolidation candidate.
UCB (Wed 07:30)
  • Catalyst watch name with firepower focused on immunology and neurology; handbook emphasises 2025‑30 EPS CAGR and need to keep replenishing the portfolio.
  • Donzakimig, Rystiggo and Bimzelx data frame UCB more as a bolt‑on acquirer / licensing player than a large take‑out target in the near term.
Recordati (Wed 11:15)
  • Explicit “potential further M&A / BD update on CVC stake” flagged in 2026 newsflow, putting capital allocation and deal appetite on the agenda.
  • Expected revenue and EBITDA ranges for 2026 leave room for targeted rare‑disease or specialty additions, consistent with its historical BD footprint.
Zealand (Wed 13:30)
  • Obesity pipeline (petrelintide, survodutide, CT‑388) dominates NPV and is co‑developed with a partner, making Zealand a structurally strategic mid‑cap in the obesity M&A theme.
  • JPM models large royalty streams and partnership economics, implicitly positioning the name as both a partner and a potential take‑out once Phase II/III risk clears.
Bachem (Wed 15:00)
  • Peptide / oligo CDMO with strong growth; 2026 newsflow items include new CEO strategy and continued emphasis on investments and contracts in GLP‑1 and peptide supply.
  • Strategically, Bachem sits in the “scarce assets” bucket for large‑cap buyers wanting secure GLP‑1/API supply, even if JPM does not explicitly flag live M&A.
Oxford Nanopore (Mon 14:15)
  • 2026 commentary highlights likely trading update at JPM and FY25 guidance, with emphasis on ONT and peer commentary; no explicit M&A flag, but technology remains highly strategic for genomics players.
Molecular Partners (Thu 10:30)
  • Handbook very explicit on partnering strategy: MP0533 in AML is expected to be out‑licensed if Phase I data are positive, with modelled 500m peak sales and 20% royalties.
  • MP0712 (DLL3 radio‑DARPin) and MP0726 (MSLN radio‑DARPin) are positioned for BD (partnering milestones, royalties), making JPM framing clearly “platform for out‑licensing” rather than stand‑alone fully integrated biotech.

How to trade the M&A angle into JPM
  • Buy firepower + need: Roche, Novartis, Sanofi, Bayer, Merck and AZN screen as best‑placed to deploy balance sheets against mid‑cap and platform stories; JPM firepower charts support this view.JPM_European_Pharma-Conference-Book-1.pdf​
  • Key “assets for sale” narratives: Lonza, Bachem, Zealand, Oxford Nanopore and Molecular Partners are portrayed as structurally positioned to monetise technology via partnerships or, longer term, strategic interest from larger buyers.